Halozyme Therapeutics Inc

Financials

Cash from operating activities 55.45 M299.44 M240.11 M388.57 M479.06 M651.56 M 651.56 M Cash from investing activities 78.35 M406.29 M487 M96.91 M262.72 M545.81 M 545.81 M Cash from financing activities 106.28 M77.86 M362.37 M407.99 M218.86 M85.17 M 85.17 M Free cash flow 52.95 M297.98 M235.3 M373.28 M468.37 M644.59 M 644.59 M

Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.

HALO

Financials

Halozyme Therapeutics Inc

News

Benchmark raises Halozyme stock price target to $90 on strong results

Monster Beverage, Other 'Gold Medal' Level Stocks Hit Record Highs, Join Best Stock Lists

Stock Market Today: Dow Up 300 Points Amid Bullish Breadth; Amer Sports Glows In Breakout (Live Coverage)

Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues

Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge (NASDAQ:HALO)

TD Cowen raises Halozyme stock price target on royalty growth

Halozyme Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:HALO) 2026-02-18

Dow Jones Futures Fall After Market Reverses Higher; Meta Deal Lifts Nvidia, Hits AI Rivals

Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript

Here's What Key Metrics Tell Us About Halozyme Therapeutics (HALO) Q4 Earnings

Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates

Halozyme earnings missed by $2.14, revenue topped estimates